Duopa (Carbidopa/Levodopa) Patent Expiration, LOE Window & CMS Spending

Duopa (Carbidopa/Levodopa) by AbbVie: Off-Patent Genericized (AB Competition), 18 AB generics, $5.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAbbVie
FDA Application & PathwayN203952 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors18
2024 CMS Total Public Spend$5.3M
2024 Medicare Part D Spend$2.8M
2024 Medicaid Spend$2.5M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.